Cargando…
The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans
The deficiently designed and conducted initial clinical development plan and the occurrence of thrombotic thrombocytopenia cases, have marked the first 12-month journey of the AstraZeneca coronavirus disease 2019 (COVID-19) vaccine after it was first administered to humans. When it was authorized, t...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277994/ https://www.ncbi.nlm.nih.gov/pubmed/35907680 http://dx.doi.org/10.1016/j.therap.2022.07.003 |